X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
humans (19) 19
analysis (18) 18
female (18) 18
male (17) 17
middle aged (16) 16
pulmonary/respiratory (15) 15
aged (12) 12
treatment outcome (12) 12
double-blind method (11) 11
genetic diversity (10) 10
respiratory system (10) 10
diabetes (9) 9
pulmonary disease, chronic obstructive - drug therapy (9) 9
safety (9) 9
tiotropium (9) 9
clinical trials (8) 8
diabetes mellitus (8) 8
efficacy (8) 8
obstructive pulmonary-disease (8) 8
type 2 diabetes (8) 8
ecology (7) 7
endocrinology & metabolism (7) 7
evolution (7) 7
glycopyrrolate - analogs & derivatives (7) 7
multidisciplinary sciences (7) 7
plant sciences (7) 7
polymer science (7) 7
primers (7) 7
species (7) 7
studies (7) 7
article (6) 6
diabetes mellitus, type 2 - drug therapy (6) 6
double-blind (6) 6
drug therapy (6) 6
evolutionary biology (6) 6
genetic markers (6) 6
genetic research (6) 6
glycopyrrolate - administration & dosage (6) 6
glycopyrrolate - adverse effects (6) 6
heterozygosity (6) 6
medicine (6) 6
phylogeny (6) 6
population genetics (6) 6
adamantane - analogs & derivatives (5) 5
adult (5) 5
biological diversity (5) 5
bronchodilator agents - administration & dosage (5) 5
cardiac & cardiovascular systems (5) 5
copd (5) 5
dapagliflozin (5) 5
drug administration schedule (5) 5
drug therapy, combination (5) 5
formoterol (5) 5
genomes (5) 5
glycopyrrolate - therapeutic use (5) 5
heart failure (5) 5
indacaterol (5) 5
indans - administration & dosage (5) 5
indans - adverse effects (5) 5
life sciences (5) 5
medical research (5) 5
metformin (5) 5
mortality (5) 5
patients (5) 5
prevention (5) 5
quinolones - administration & dosage (5) 5
quinolones - adverse effects (5) 5
research article (5) 5
science (5) 5
trial (5) 5
adamantane - adverse effects (4) 4
administration, inhalation (4) 4
behavior (4) 4
benzhydryl compounds - adverse effects (4) 4
biodiversity (4) 4
blood glucose - drug effects (4) 4
bronchodilator agents - adverse effects (4) 4
bronchodilator agents - therapeutic use (4) 4
cardiovascular disease (4) 4
chemistry (4) 4
chloroplast dna (4) 4
clinical medicine (4) 4
combination (4) 4
conservation genetics (4) 4
daily nva237 (4) 4
dipeptides - adverse effects (4) 4
dosage and administration (4) 4
genes (4) 4
glucosides - adverse effects (4) 4
glycopyrronium (4) 4
heart diseases (4) 4
hypoglycemia (4) 4
hypoglycemia - chemically induced (4) 4
hypoglycemic agents - adverse effects (4) 4
hypoglycemic agents - therapeutic use (4) 4
indans - therapeutic use (4) 4
komposit (4) 4
laboratories (4) 4
materials science, textiles (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
OBJECTIVE To compare the efficacy and safety of treatment with dapagliflozin versus that with placebo add-on to saxagliptin plus metformin in patients whose... 
BODY-WEIGHT | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | PIOGLITAZONE | EFFICACY | SAFETY | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | 24-WEEK | MELLITUS | INADEQUATE GLYCEMIC CONTROL | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 199 - 209
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 23, pp. 2628 - 2639
Background: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with... 
heart failure | diabetes mellitus | sodium glucose cotransporter-2 inhibitors | death | observational studies | SGLT-2 inhibitor | CARDIAC & CARDIOVASCULAR SYSTEMS | SEVERE HYPOGLYCEMIA | SULFONYLUREA | INITIATION | ALL-CAUSE MORTALITY | ORGANIZATION | JAPANESE HOSPITAL DATABASE | ASIA | LOWER RISK | DPP-4 INHIBITORS | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Male | Diabetes Mellitus, Type 2 - epidemiology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Internationality | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Electronic Health Records | Cohort Studies | Glucose | Chemical vapor deposition | Analysis | Dextrose | Heart | Drugs | Laboratories | Identification methods | Personal health | Clinical trials | Medical records | Subgroups | Data bases | Matching | Confidence intervals | Risk assessment | Diuretics | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Health insurance | Stroke | Payment systems | Diabetes mellitus | Mortality | Health risks | Patients | Prescription drugs | Hospitals | Inhibitors | Sodium | Death | Diabetes | Clinical medicine | Cardiovascular diseases | Pharmaceuticals
Journal Article
DIABETES CARE, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2018 - 2024
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 10, pp. 1558 - 1567
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 22, pp. 2497 - 2506
Journal Article
Chest, ISSN 0012-3692, 2014, Volume 145, Issue 3, pp. 403A-1 - 403A-2
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1542 - 1546
The safety of triple oral therapy with dapagliflozin plus saxagliptin plus metformin versus dual therapy with dapagliflozin or saxagliptin plus metformin was... 
SGLT‐2 inhibitor | metformin | DPP‐4 inhibitor | type 2 diabetes | dapagliflozin | DPP-4 inhibitor | SGLT-2 inhibitor | EVENTS | EFFICACY | DOUBLE-BLIND TRIAL | PLUS METFORMIN | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS | Benzhydryl Compounds - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptides - administration & dosage | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Urinary tract infections | Hypoglycemic agents | Safety and security measures | Analysis | Diabetes therapy | Diabetes mellitus | Clinical trials | Urinary tract | Safety | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | Brief Reports | Brief Report
Journal Article
Diabetes, ISSN 0012-1797, 05/2018, Volume 67, Issue Supplement 1, p. 1582
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2019, Volume 21, Issue 11, pp. 2474 - 2485
Aim To evaluate treatment data from DISCOVER (NCT02322762 and NCT02226822), a global, prospective, observational study programme of patients with type 2... 
population study | antidiabetic drug | type 2 diabetes | Glucose transporter | Peptidase | Sodium | Glucagon | Diabetes mellitus | Socio-economic aspects | Diabetes | Metformin | Regression analysis | Diabetes mellitus (non-insulin dependent) | Patients | Index Medicus
Journal Article